A multicenter experience with generic mycophenolate mofetil conversion in stable liver transplant recipients

Area of Science:

• Transplantation Medicine
• Pharmacoeconomics
• Clinical Pharmacy

Background:

• Generic substitution of medications offers significant cost savings and is a recognized medical practice.
• Mycophenolate mofetil (MMF) is a crucial immunosuppressant in liver transplant recipients.
• Evaluating the safety and efficacy of generic formulations is vital for patient care and healthcare economics.

Purpose of the Study:

• To assess the clinical and safety outcomes of liver transplant patients switching from brand-name Cellcept to generic My-rept (MMF).
• To determine if generic MMF maintains comparable efficacy and safety profiles to the originator product in a stable post-transplant population.

Main Methods:

• Prospective data collection from 154 stable adult liver transplant recipients over two years (April 2010 - September 2012).
• Evaluation of complications, safety parameters, quality of life, and patient-reported outcomes post-MMF formulation conversion.
• Institutional Review Board approval was obtained from all participating centers.

Main Results:

• A low incidence of drug-related complications (5.19%) was observed, predominantly mild gastrointestinal issues.
• No significant differences in gastrointestinal symptoms or quality-of-life scores were found pre- and post-conversion.
• Over 90% of patients reported similar experiences with both brand-name and generic MMF formulations.
• Serious adverse events occurred in 5.8% of patients; acute rejection in two patients with no graft loss or mortality.

Conclusions:

• Generic MMF demonstrates comparable efficacy and safety to the brand-name formulation in liver transplant recipients.
• The findings support the conversion from brand-name MMF to generic MMF, encouraging its wider adoption.
• This transition is advisable given the comparable clinical outcomes and favorable safety profile observed in this study.